GYN · Organ at risk

Rectum

Educational Summary

Dose constraints

Cervix — Definitive Chemoradiation

ScheduleConstraintSource
45–50.4 Gy / 25–28 fx
Pelvis ± nodal boost
D50% ≤45 Gy, D0.03 cc ≤50 GyNRG cervix RT template
V40 Gy <75%, V30 Gy <95%EMBRACE II

Quoted from NRG cervix RT template and EMBRACE II, checked 2026-09-30. Full table with references →

Endometrium & Cervix — Post-operative

ScheduleConstraintSource
45–50.4 Gy / 25–28 fx
Post-operative pelvis
V40 Gy ≤80%NRG endometrial RT template

Quoted from NRG endometrial RT template, checked 2026-09-30. Full table with references →

Vulva

ScheduleConstraintSource
45–50.4 Gy / 25–28 fx + boost
Composite plan (SIB or sequential boost)
D60% ≤45 Gy, D0.03 cc ≤60 GyNRG vulva RT template

Quoted from NRG vulva RT template, checked 2026-09-30. Full table with references →

Anatomy

The final segment of the large bowel, running from the rectosigmoid junction down through the pelvis to the anal canal. It lies directly behind the prostate and seminal vesicles, separated from them only by a thin fascial layer (Denonvilliers' fascia), which is why the anterior rectal wall sits so close to the prostate target.

Function in the body

The rectum stores stool before it leaves the body.

Why it matters

For prostate treatment the rectum is usually the organ that limits the plan. Late rectal toxicity — bleeding, urgency, frequency — is one of the side effects most closely tied to dose escalation, and it is driven mainly by how much of the rectum receives high dose. That is why rectal limits are written as a ladder of Vx values rather than one number: the DVH should stay under every rung.

Because the rectum's filling changes from day to day, the rectum you contour on the planning CT is a snapshot. Consistent bowel preparation, rectal spacers and daily image guidance all aim to make the treated anatomy match the planned one.

In gynecologic treatment the rectum lies directly behind the cervix, vagina and vaginal cuff. In post-operative plans the vaginal ITV may include the front wall of the rectum, so high rectal volumes are expected. In cervix brachytherapy the rectum's D2cc — the minimum dose to the most exposed 2 cc — is one of the main planning limits, added to the external beam dose in EQD2.

How to contour

Gay 2012 gives two versions:

  • Rectum (GU): from the lowest level of the ischial tuberosities up to where the rectum loses its round shape on axial images and joins the sigmoid in front.
  • AnoRectum (GYN): the same top, but starting at the anal verge marked at simulation, so it includes the anus.

Timmerman 2022 (Tables 8–11, written for its SBRT dose tables): one structure including the rectal wall and all contents; its Table 9 instruction reads "start contouring 10 cm superior to PTV then inferior to anal sphincter." Make sure your rectum and anus contours match the definitions behind your limits.

Review articleSource Verified
A Story of Hypofractionation and the Table on the Wall
Timmerman R · UT Southwestern Medical Center · 2022

An editorial history of the UT Southwestern SABR constraint tables — often called the “Timmerman tables” — covering how they were developed and revised, and their relationship to AAPM TG-101 and NRG/RTOG protocols. Tables 2–11 separate serial tissues (listed with a volume, a volume max and a max point dose) from parallel tissues (listed with a critical volume and a critical-volume dose max). In Tables 2–7 a footnote defines “point” as ≤0.035 cm³; Tables 8–11 add a contouring-instructions column for each structure.

Further reading

  • QUANTEC — QUANTEC — Quantitative Analyses of Normal Tissue Effects in the Clinic Source
  • ENZARAD protocol — ENZARAD (ANZUP 1303): a randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer Source
  • CHHiP (Dearnaley 2016) — Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Source
  • PACE-B — Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial Source
  • NRG cervix RT template — NRG Oncology Protocol Development Template for Radiation Therapy — Gynecological Cancer: Cervix, Uterine Cervix Source
  • EMBRACE II — The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies Source

Related concepts